Improve your screening know-how with TTP LabTech at Screening Europe 2010
News Jan 28, 2010
On 11th February, TTP LabTech will be offering a free workshop entitled “The Identification of novel cancer targets using a rapid, high-content, genome wide RNAi screen”. Based on the Acumen platform, this workshop will describe how information identifying high quality hits can be accessed quickly and easily either by in-house data generation or via an outsourced service.
In addition, Gaetan Touyer, Head of Screening Group, Vitry Research Center at Sanofi Aventis will present a study of five screening assays, including cell-based protein-protein interaction, homogeneous cell receptor ligand binding and cell cycle analysis at 11.45am on the 12th February. The talk explores his experiences of integrating the Acumen eX3 microplate cytometer into an HTS platform to achieve a screening throughput of tens of thousands of wells per day using a complex yet controlled process with multiple experimental steps.
Visitors to the TTP LabTech stand #12, will also be able to find out more about the new high content screening service now on offer. Based on the industry-proven Acumen platform, this service offers a highly flexible approach to cell-based screening, providing high-throughput, content-rich and highly multiplexed data for applications such as target identification, primary screening and preclinical toxicology.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE